key: cord-0724319-y2h0h35j authors: Bianco, Gabriele; Boattini, Matteo; Barbui, Anna Maria; Scozzari, Gitana; Riccardini, Franco; Coggiola, Maurizio; Lupia, Enrico; Cavallo, Rossana; Costa, Cristina title: Evaluation of an antigen-based test for hospital point-of-care diagnosis of SARS-CoV-2 infection date: 2021-04-21 journal: J Clin Virol DOI: 10.1016/j.jcv.2021.104838 sha: f0e1a105ae1caa2878cca7f3c0a08162e4f01309 doc_id: 724319 cord_uid: y2h0h35j BACKGROUND: An accurate diagnosis is essential to identify and manage SARS-CoV-2 infected patients and implement infection control measures. Although real-time reverse transcription polymerase chain reaction (RT-PCR) is the current recommended laboratory method, several rapid antigen point-of-care tests (POCTs) were developed as frontline testing for SARS-CoV-2 infection diagnosis. OBJECTIVES: The aim of this study was to assess a recently CE-approved POCT, SARS-CoV-2 Ag Test on the LumiraDx™ Platform (LumiraDx GmbH, Cologne, Germany) for the identification of SARS-COV-2 infected subjects at hospital setting. METHODS: LumiraDx POCT was implemented in three hospital settings: adult and pediatric emergency departments and occupational medicine department along two-month period during the second peak of Italian SARS-CoV-2 pandemic. Rapid antigen testing was performed on direct nasal swabs and results were compared with those obtained by Xpert Xpress SARS-CoV-2 assay. RESULTS: Overall sensitivity, specificity, NPV and PPV were 90.3%, 92.1%, 95.1%, and 84.9%, respectively, compared to reference method. Sensitivity, specificity, PPV and NPV for symptomatic group were 89.3% [95% IC 84.2-93.3], 88.2% [95% IC 72.5-96.7], 97.8% [95% IC 94.6-99.1], and 58.8% [95% IC 48.4-68.5], respectively. Sensitivity, specificity, PPV and NPV for asymptomatic group were 92.1% [95% IC 85-96.5], 92.3% [95% IC 89.9-94.4], 67.9% [95% IC 61.3-73.8], and 98.5% [95% IC 97.1-99.2], respectively. False positive and negative antigen testing results in both symptomatic and asymptomatic group were observed. CONCLUSION: SARS-CoV-2 Ag POCT may represent an interesting tool to rapidly identify symptomatic or asymptomatic infected subjects. However, in hospital setting in which false negative or false positive results may have relevant implications, confirmatory NAAT always remains necessary for the appropriate management of patients. Conclusion: SARS-CoV-2 Ag POCT may represent an interesting tool to rapidly identify symptomatic or asymptomatic infected subjects. However, in hospital setting in which false negative or false positive results may have relevant implications, confirmatory NAAT always remains necessary for the appropriate management of patients. Keywords: SARS-CoV-2, Antigen test, Point-of-care-testing, hospital screening, healthcare workers The coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a major public health emergency worldwide [1, 2] . As the clinical manifestation of SARS-CoV-2 infection is highly variable, from asymptomatic to severe acute respiratory distress syndrome, an accurate diagnosis is crucial to identify and manage infected patients and implement infection control measures to limit SARS-CoV-2 spread. Probe-based realtime reverse transcription polymerase chain reaction (RT-PCR) has been the gold standard method for SARS-CoV-2 detection and widely used for screening, as recommended by WHO and CDC [3, 4] . However, RT-PCR as well as the other molecular assays (i.e. loop-mediated isothermal amplification-based assay [RT-LAMP], microarray, and high-throughput sequencing) are costly, often time consuming and require special equipment and skilled laboratory personnel. Furthermore, growing SARS-CoV-2 pandemic and the dearth of molecular testing capacity, as well as reagents around the world, demanded the development of point-of-care tests (POCTs) as frontline testing for SARS-CoV-2 infection diagnosis. Antigen-detecting rapid diagnostic tests are relatively inexpensive, simple to perform and enable obtaining point-of-care results within few minutes (5-13). The aim of this study was to assess a recently CE-approved POCT, SARS-CoV-2 Ag Test on the LumiraDx™ Platform (LumiraDx GmbH, Cologne, Germany) for the identification of SARS-COV-2 infected individuals in comparison with the reference method RT-PCR. The prospective controlled observational study was conducted at the University Hospital Città della Salute e della Scienza di Torino, Turin (Italy), which is the largest tertiary care facility in Europe. Three hospital settings were considered: adult and pediatric emergency departments and occupational medicine department along the period October 2019 to December 2019, during the second peak of Italian SARS-CoV-2 pandemic. The LumiraDx™ SARS-CoV-2 Antigen Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen of SARS-CoV-2 in nasal and nasopharyngeal swab specimens. It exploits microfluidic test strips that contain specific antibodies to form an immunoassay complex that uses a fluorescent latex signal to detect the nucleocapsid protein antigen in the test sample. It was performed on direct nasal swabs in the three wards by Overall, 907 patients were evaluated, including 656 and 165 subjects at the adult and pediatric emergency departments, respectively, and 86 healthcare workers at the occupational medicine unit. The mean age of the study population was 47.9 (range: 2 months-94 years) with a sex ratio of 0.8 (402 male and 505 women). At specimen collection, 676 (74.5%) participants were asymptomatic and 231 (25.5%) reported experiencing one or more COVID-19 symptoms. The median interval from symptom onset to specimen collection was 4 days (interquartile range 2-7). According to RT-PCR results, 298 (32.9%) participants were positive to SARS-CoV-2, of which 197 (85.3%) and 101 (14.9%) with symptoms and no symptoms, respectively ( False positive antigen testing results were observed in both symptomatic and asymptomatic group, 1.7% (n=4) and 6.5% (n=44), respectively. None of the patients positive by LumiraDx™ POCT tested positive by molecular testing on the second nasopharyngeal swab collected 24h after. False negative antigen testing results were also observed in both symptomatic and asymptomatic group, 9 .1% (n=21) and 1.1% (n=8), respectively. In the ongoing pandemic context of COVID-19, diagnostic testing for SARS-CoV-2 is crucial to limit the spread of the virus and manage infected patients. Several rapid tests based on SARS-CoV-2 proteins detection have been developed and are now available on the market. Despite rapid antigen tests were reported to have high specificity, a wide range of sensitivity, often lower than declared by the manufacturers, was reported [8] [9] [10] [11] [12] [13] . In this evaluation, sensitivity of LumiraDx™ POCT was acceptable (90.3%) when compared to RT-PCR, slightly lower than reported by the manufacturer (93.1%) but significantly higher than most evaluated rapid antigen-based tests [7-11, 12,13] .  All named authors have seen and agreed to the submitted version of the paper; all who are included in the acknowledgements section, or as providers of personal communications, have agreed to those inclusions; the material is original, unpublished and has not been submitted elsewhere.  No material which has been published elsewhere is contained in the article.  No material related to commercial products is contained in the article.  No pending publication of the material in conference proceedings, letters to journals and brief communications etc. is contained in the article.  All authors declare no conflict of interest and no sources of funding.  The authors received no financial support for the research. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no conflicts of interest. A new coronavirus associated with human respiratory disease in China WHO Director-General's opening remarks at the media briefing on COVID-19 -11 Laboratory testing for coronavirus disease (COVID-19) in suspected human cases CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19 Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2 Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis